Protalix BioTherapeutics, Inc.PLXEarnings & Financial Report
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX Q3 2025 Key Financial Metrics
Revenue
$17.9M
Gross Profit
$9.5M
Operating Profit
$2.1M
Net Profit
$2.4M
Gross Margin
53.4%
Operating Margin
11.9%
Net Margin
13.2%
YoY Growth
-0.6%
EPS
$0.03
Financial Flow
Protalix BioTherapeutics, Inc. Q3 2025 Financial Summary
Protalix BioTherapeutics, Inc. reported revenue of $17.9M for Q3 2025, with a net profit of $2.4M (13.2% margin). Cost of goods sold was $8.3M, operating expenses totaled $7.4M.
Key Financial Metrics
| Total Revenue | $17.9M |
|---|---|
| Net Profit | $2.4M |
| Gross Margin | 53.4% |
| Operating Margin | 11.9% |
| Report Period | Q3 2025 |
Protalix BioTherapeutics, Inc. Annual Revenue by Year
Protalix BioTherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $53.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $53.4M |
| 2023 | $65.5M |
| 2022 | $47.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M | $3.7M | $13.5M | $18.0M | $18.2M | $10.1M | $15.7M | $17.9M |
| YoY Growth | 21.7% | -60.9% | -61.6% | 73.6% | 73.7% | 169.8% | 16.2% | -0.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $84.4M | $89.8M | $91.5M | $61.6M | $73.4M | $73.9M | $78.5M | $82.3M |
| Liabilities | $50.9M | $60.0M | $63.0M | $29.1M | $30.2M | $28.7M | $28.6M | $29.4M |
| Equity | $33.6M | $29.8M | $28.6M | $32.4M | $43.2M | $45.2M | $49.9M | $52.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $3.6M | $4.2M | $-3.6M | $4.1M | $4.0M | $-5.1M | $-5.2M | $-3.7M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M